Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
AIDS (London, England)|June 1, 1994
Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicityB N Stretcher, A J Pesce, P T Frame, et al.
Antimicrobial Agents and Chemotherapy|November 16, 2001
Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavirB M Sadler, C Gillotin, Y Lou, et al.
AIDS (London, England)|June 16, 2001
Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteersB M Sadler, P J Piliero, S L Preston, et al.
Antimicrobial Agents and Chemotherapy|December 3, 1999
Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance studyJ A McDowell, G E Chittick, J R Ravitch, et al.
AIDS (London, England)|May 1, 1996
A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)D S Stein, D G Fish, J A Bilello, et al.
The Journal of Infectious Diseases|January 1, 1994
Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoringM D Hughes, D S Stein, H M Gundacker, et al.
Pharmacotherapy|August 24, 1999
Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of foodG E Chittick, C Gillotin, J A McDowell, et al.
Antimicrobial Agents and Chemotherapy|January 18, 2002
Pharmacodynamics of abacavir in an in vitro hollow-fiber model systemG L Drusano, P A Bilello, W T Symonds, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1987
Oral ribavirin treatment of influenza A and BD S Stein, C M Creticos, G G Jackson, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|August 31, 2012
Disposition and metabolism of [¹⁴C]PTZ601 in healthy volunteersJ Flarakos, L S L Ting, Y Du, et al.
Pageof 10